109 related articles for article (PubMed ID: 37060785)
1. Pyrimido[1,2-a]benzimidazoles as inhibitors of oncoproteins ubiquitin specific protease 5 and MYCN in the childhood cancer neuroblastoma.
Gadde S; Kleynhans A; Holien JK; Bhadbhade M; Nguyen PLD; Mittra R; Yu TT; Carter DR; Parker MW; Marshall GM; Cheung BB; Kumar N
Bioorg Chem; 2023 Jul; 136():106462. PubMed ID: 37060785
[TBL] [Abstract][Full Text] [Related]
2. A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma.
Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM
Oncogene; 2021 Apr; 40(13):2367-2381. PubMed ID: 33658627
[TBL] [Abstract][Full Text] [Related]
3. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
4. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
[TBL] [Abstract][Full Text] [Related]
5. HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma.
Tavana O; Li D; Dai C; Lopez G; Banerjee D; Kon N; Chen C; Califano A; Yamashiro DJ; Sun H; Gu W
Nat Med; 2016 Oct; 22(10):1180-1186. PubMed ID: 27618649
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
7. An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability.
Nagy Z; Seneviratne JA; Kanikevich M; Chang W; Mayoh C; Venkat P; Du Y; Jiang C; Salib A; Koach J; Carter DR; Mittra R; Liu T; Parker MW; Cheung BB; Marshall GM
Nat Commun; 2021 Mar; 12(1):1881. PubMed ID: 33767157
[TBL] [Abstract][Full Text] [Related]
8. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
9. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
10.
De Rosa P; Severi F; Zadran SK; Russo M; Aloisi S; Rigamonti A; Capranico G; Milazzo G; Perini G
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982482
[TBL] [Abstract][Full Text] [Related]
11. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
[TBL] [Abstract][Full Text] [Related]
12. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of small molecule inhibitors of LSD1 for use against MYCN-expressing neuroblastoma.
Mills CM; Turner J; Piña IC; Garrabrant KA; Geerts D; Bachmann AS; Peterson YK; Woster PM
Eur J Med Chem; 2022 Dec; 244():114818. PubMed ID: 36223680
[TBL] [Abstract][Full Text] [Related]
14. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
[TBL] [Abstract][Full Text] [Related]
15. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.
Lodrini M; Oehme I; Schroeder C; Milde T; Schier MC; Kopp-Schneider A; Schulte JH; Fischer M; De Preter K; Pattyn F; Castoldi M; Muckenthaler MU; Kulozik AE; Westermann F; Witt O; Deubzer HE
Nucleic Acids Res; 2013 Jul; 41(12):6018-33. PubMed ID: 23625969
[TBL] [Abstract][Full Text] [Related]
16. Reversing the HDAC-inhibitor mediated metabolic escape in MYCN-amplified neuroblastoma.
Bishayee K; Nazim UM; Kumar V; Kang J; Kim J; Huh SO; Sadra A
Biomed Pharmacother; 2022 Jun; 150():113032. PubMed ID: 35486977
[TBL] [Abstract][Full Text] [Related]
17. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
Cortés C; Kozma SC; Tauler A; Ambrosio S
Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
[TBL] [Abstract][Full Text] [Related]
18. YM155 inhibits neuroblastoma growth through degradation of MYCN: A new role as a USP7 inhibitor.
Li X; Yang F; He N; Zhang M; Lv Y; Yu Y; Dong Q; Hou X; Hao Y; An Z; Zhang H; Yang Z; Zhai H; Guo D; Cao Z; Jiang VC; Chen Y
Eur J Pharm Sci; 2023 Feb; 181():106343. PubMed ID: 36436754
[TBL] [Abstract][Full Text] [Related]
19. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ
Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605
[TBL] [Abstract][Full Text] [Related]
20. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
